Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Four-Week Unstructured Break Improved Athletic Performance in Collegiate Rugby Players.

Jensen CD, Gleason D, VanNess M.

J Strength Cond Res. 2018 Jun;32(6):1671-1677. doi: 10.1519/JSC.0000000000002417.

PMID:
29373428
2.

Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.

Gleason DF, Mellinger GT; Veterans Administration Cooperative Urological Research Group.

J Urol. 2017 Feb;197(2S):S134-S139. doi: 10.1016/j.juro.2016.10.099. Epub 2016 Dec 21. No abstract available.

PMID:
28012760
3.

CC2D1A regulates human intellectual and social function as well as NF-κB signaling homeostasis.

Manzini MC, Xiong L, Shaheen R, Tambunan DE, Di Costanzo S, Mitisalis V, Tischfield DJ, Cinquino A, Ghaziuddin M, Christian M, Jiang Q, Laurent S, Nanjiani ZA, Rasheed S, Hill RS, Lizarraga SB, Gleason D, Sabbagh D, Salih MA, Alkuraya FS, Walsh CA.

Cell Rep. 2014 Aug 7;8(3):647-55. doi: 10.1016/j.celrep.2014.06.039. Epub 2014 Jul 24.

4.

CHMP1A encodes an essential regulator of BMI1-INK4A in cerebellar development.

Mochida GH, Ganesh VS, de Michelena MI, Dias H, Atabay KD, Kathrein KL, Huang HT, Hill RS, Felie JM, Rakiec D, Gleason D, Hill AD, Malik AN, Barry BJ, Partlow JN, Tan WH, Glader LJ, Barkovich AJ, Dobyns WB, Zon LI, Walsh CA.

Nat Genet. 2012 Nov;44(11):1260-4. doi: 10.1038/ng.2425. Epub 2012 Sep 30.

5.

A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts.

Mochida GH, Ganesh VS, Felie JM, Gleason D, Hill RS, Clapham KR, Rakiec D, Tan WH, Akawi N, Al-Saffar M, Partlow JN, Tinschert S, Barkovich AJ, Ali B, Al-Gazali L, Walsh CA.

Am J Hum Genet. 2010 Dec 10;87(6):882-9. doi: 10.1016/j.ajhg.2010.10.026. Epub 2010 Nov 25.

6.

Candidate gene sequencing of LHX2, HESX1, and SOX2 in a large schizencephaly cohort.

Mellado C, Poduri A, Gleason D, Elhosary PC, Barry BJ, Partlow JN, Chang BS, Shaw GM, Barkovich AJ, Walsh CA.

Am J Med Genet A. 2010 Nov;152A(11):2736-42. doi: 10.1002/ajmg.a.33684.

7.

Developmental and degenerative features in a complicated spastic paraplegia.

Manzini MC, Rajab A, Maynard TM, Mochida GH, Tan WH, Nasir R, Hill RS, Gleason D, Al Saffar M, Partlow JN, Barry BJ, Vernon M, LaMantia AS, Walsh CA.

Ann Neurol. 2010 Apr;67(4):516-25. doi: 10.1002/ana.21923.

8.

Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth.

Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, Callahan W, Partington A, Fellows K, Ouellette L, Zhidro S, Goodrow C, Smith A, Sullivan K, Simone P, Le L, Vezuli B, Zohni M, West E, Gleason D, Bryan B.

Oncol Rep. 2010 Mar;23(3):861-7.

PMID:
20127030
9.

Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model.

Guerra-Crespo M, Sistos A, Gleason D, Fallon JH.

J Stroke Cerebrovasc Dis. 2010 Jan;19(1):3-9. doi: 10.1016/j.jstrokecerebrovasdis.2009.09.005.

PMID:
20123220
10.

Mutations in PNKP cause microcephaly, seizures and defects in DNA repair.

Shen J, Gilmore EC, Marshall CA, Haddadin M, Reynolds JJ, Eyaid W, Bodell A, Barry B, Gleason D, Allen K, Ganesh VS, Chang BS, Grix A, Hill RS, Topcu M, Caldecott KW, Barkovich AJ, Walsh CA.

Nat Genet. 2010 Mar;42(3):245-9. doi: 10.1038/ng.526. Epub 2010 Jan 31.

11.

A truncating mutation of TRAPPC9 is associated with autosomal-recessive intellectual disability and postnatal microcephaly.

Mochida GH, Mahajnah M, Hill AD, Basel-Vanagaite L, Gleason D, Hill RS, Bodell A, Crosier M, Straussberg R, Walsh CA.

Am J Hum Genet. 2009 Dec;85(6):897-902. doi: 10.1016/j.ajhg.2009.10.027.

12.

Climate change, coral reef ecosystems, and management options for marine protected areas.

Keller BD, Gleason DF, McLeod E, Woodley CM, Airamé S, Causey BD, Friedlander AM, Grober-Dunsmore R, Johnson JE, Miller SL, Steneck RS.

Environ Manage. 2009 Dec;44(6):1069-88. doi: 10.1007/s00267-009-9346-0.

13.

Transforming growth factor-alpha induces neurogenesis and behavioral improvement in a chronic stroke model.

Guerra-Crespo M, Gleason D, Sistos A, Toosky T, Solaroglu I, Zhang JH, Bryant PJ, Fallon JH.

Neuroscience. 2009 May 5;160(2):470-83. doi: 10.1016/j.neuroscience.2009.02.029. Epub 2009 Feb 25.

PMID:
19248822
14.

Ethnically diverse causes of Walker-Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East.

Manzini MC, Gleason D, Chang BS, Hill RS, Barry BJ, Partlow JN, Poduri A, Currier S, Galvin-Parton P, Shapiro LR, Schmidt K, Davis JG, Basel-Vanagaite L, Seidahmed MZ, Salih MA, Dobyns WB, Walsh CA.

Hum Mutat. 2008 Nov;29(11):E231-41. doi: 10.1002/humu.20844.

15.

Disposable plastic rodent feeders for use in an automated filling system.

Toler J, Gleason D, Clare L, Buckham S, DeWit R.

Lab Anim (NY). 2008 Sep;37(9):415-9. doi: 10.1038/laban0908-415.

PMID:
18719694
16.

Ependymal stem cells divide asymmetrically and transfer progeny into the subventricular zone when activated by injury.

Gleason D, Fallon JH, Guerra M, Liu JC, Bryant PJ.

Neuroscience. 2008 Sep 22;156(1):81-8. doi: 10.1016/j.neuroscience.2008.06.065. Epub 2008 Jul 11.

PMID:
18682279
17.

Identifying autism loci and genes by tracing recent shared ancestry.

Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, Al-Saad S, Ware J, Joseph RM, Greenblatt R, Gleason D, Ertelt JA, Apse KA, Bodell A, Partlow JN, Barry B, Yao H, Markianos K, Ferland RJ, Greenberg ME, Walsh CA.

Science. 2008 Jul 11;321(5886):218-23. doi: 10.1126/science.1157657. Erratum in: Science. 2010 Dec 24;330(6012):1746.

18.

Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.

Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, Witjes JA.

J Urol. 2008 Jul;180(1):116-20. doi: 10.1016/j.juro.2008.03.031. Epub 2008 May 15.

PMID:
18485407
19.

Latitudinal variation in spongivorous fishes and the effectiveness of sponge chemical defenses.

Ruzicka R, Gleason DF.

Oecologia. 2008 Jan;154(4):785-94. Epub 2007 Oct 25.

PMID:
17960425
20.

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

Saad F, Chen YM, Gleason DM, Chin J.

Clin Genitourin Cancer. 2007 Sep;5(6):390-6.

PMID:
17956712
21.

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J.

J Urol. 2006 Jul;176(1):75-80.

PMID:
16753373
22.

Development of a coral cDNA array to examine gene expression profiles in Montastraea faveolata exposed to environmental stress.

Edge SE, Morgan MB, Gleason DF, Snell TW.

Mar Pollut Bull. 2005;51(5-7):507-23. Epub 2005 Aug 22.

PMID:
16115654
23.

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M; Zoledronic Acid Prostate Cancer Study Group.

J Natl Cancer Inst. 2004 Jun 2;96(11):879-82.

PMID:
15173273
24.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group.

Urology. 2004 May;63(5):928-33.

PMID:
15134983
25.

Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases.

Grant SA, Breslin DS, MacLeod DB, Gleason D, Martin G.

J Clin Anesth. 2004 Mar;16(2):124-6.

PMID:
15110375
26.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
27.

Ionic reaction of halogens with terminal alkenes: the effect of electron-withdrawing fluorine substituents on the bonding of halonium ions.

Shellhamer DF, Allen JL, Allen RD, Gleason DC, O'Neil Schlosser C, Powers BJ, Probst JW, Rhodes MC, Ryan AJ, Titterington PK, Vaughan GG, Heasley VL.

J Org Chem. 2003 May 16;68(10):3932-7.

PMID:
12737574
28.

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.

Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC.

Clin Ther. 2002 Nov;24(11):1902-14.

PMID:
12501882
29.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.

Cancer Invest. 2002;20 Suppl 2:45-54. Review.

PMID:
12442349
30.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group.

J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68.

PMID:
12359855
31.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group.

J Urol. 2002 Aug;168(2):429-35. Erratum in: J Urol 2002 Dec;168(6):2558. J Urol 2002 Oct;168;4(Pt 1):1510.

PMID:
12131282
32.

Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.

Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Gleason DF.

Cancer. 2002 Jun 15;94(12):3141-9.

33.

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974.

Gleason DF, Mellinger GT; Veterans Administration Cooperative Urological Research Group.

J Urol. 2002 Feb;167(2 Pt 2):953-8; discussion 959. No abstract available.

PMID:
11905924
34.

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.

McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group.

Urology. 2001 Nov;58(5):756-61.

PMID:
11711355
35.

Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.

Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF, Gleason DF.

Prostate. 2001 Sep 15;48(4):274-84.

PMID:
11536307
36.

A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere.

Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Snyder J, Gleason D, Killion D, Macdonald J, Khan AU, Diokno A, Sirls LT, Saltzstein D.

Urology. 2001 Jul;58(1):12-5.

PMID:
11445471
37.

Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis.

Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ.

Cancer. 2001 Jun 15;91(12):2302-14.

PMID:
11413519
39.

Taste preconditioning augments odor-aversion learning.

Batsell WR Jr, Paschall GY, Gleason DI, Batson JD.

J Exp Psychol Anim Behav Process. 2001 Jan;27(1):30-47.

PMID:
11199513
40.

Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993.

Gilliland FD, Gleason DF, Hunt WC, Stone N, Harlan LC, Key CR.

J Urol. 2001 Mar;165(3):846-50.

PMID:
11176484
41.

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.

Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R.

Urology. 2000 May;55(5):639-42.

PMID:
10792069
42.

The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.

Sinha AA, Quast BJ, Korkowski JC, Wilson MJ, Reddy PK, Ewing SL, Sloane BF, Gleason DF.

Anticancer Res. 1999 Jul-Aug;19(4B):2821-9.

PMID:
10652560
43.

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.

Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S.

Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283-9.

PMID:
10543335
44.
45.

Major ambulatory surgery with continuous regional anesthesia and a disposable infusion pump.

Klein SM, Greengrass RA, Gleason DH, Nunley JA, Steele SM.

Anesthesiology. 1999 Aug;91(2):563-5. No abstract available.

PMID:
10443623
46.

The external urethral barrier for stress incontinence: a multicenter trial of safety and efficacy. Miniguard Investigators Group.

Brubaker L, Harris T, Gleason D, Newman D, North B.

Obstet Gynecol. 1999 Jun;93(6):932-7.

PMID:
10362157
47.

Lumbar plexus and sciatic nerve block for knee arthroplasty: comparison of ropivacaine and bupivacaine.

Greengrass RA, Klein SM, D'Ercole FJ, Gleason DG, Shimer CL, Steele SM.

Can J Anaesth. 1998 Nov;45(11):1094-6.

PMID:
10021959
48.

A comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block.

Klein SM, Greengrass RA, Steele SM, D'Ercole FJ, Speer KP, Gleason DH, DeLong ER, Warner DS.

Anesth Analg. 1998 Dec;87(6):1316-9.

PMID:
9842819
49.

Supplemental Content

Loading ...
Support Center